Skip to main content
. Author manuscript; available in PMC: 2010 Dec 1.
Published in final edited form as: Oncogene. 2010 Mar 15;29(22):3196–3207. doi: 10.1038/onc.2010.73

Figure 1.

Figure 1

Dasatinib inhibits calvarial osteoblast (PMOs) proliferation. A, cell density and morphologic characteristics after treatment of PMOs with various concentrations of dasatinib for 72 h. PMOs were cultured in 10% FBS or in 0.1% BSA as indicated. B, quantification of cell numbers. C. Time course of effect of dasatinib on PMOs proliferation. The PMOs were cultured in 10% FBS and treated without or with 50 nM dasatinib. Data are means ± SD. *P < 0.05 vs. control (DMSO). The experiment was repeated three times with similar results.